<?xml version='1.0' encoding='utf-8'?>
<document id="9155533"><sentence text="In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines."><entity charOffset="20-30" id="DDI-PubMed.9155533.s1.e0" text="paclitaxel" /><entity charOffset="32-37" id="DDI-PubMed.9155533.s1.e1" text="Taxol" /><entity charOffset="43-54" id="DDI-PubMed.9155533.s1.e2" text="vinorelbine" /><entity charOffset="56-65" id="DDI-PubMed.9155533.s1.e3" text="navelbine" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e0" e2="DDI-PubMed.9155533.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e0" e2="DDI-PubMed.9155533.s1.e1" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e0" e2="DDI-PubMed.9155533.s1.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e0" e2="DDI-PubMed.9155533.s1.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e1" e2="DDI-PubMed.9155533.s1.e1" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e1" e2="DDI-PubMed.9155533.s1.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e1" e2="DDI-PubMed.9155533.s1.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e2" e2="DDI-PubMed.9155533.s1.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s1.e2" e2="DDI-PubMed.9155533.s1.e3" /></sentence><sentence text="Paclitaxel (PTXL) (Taxol), a taxane, and vinorelbine (VRB), a semisynthetic vinca alkaloid drug, have tubulin as their common intracellular target, but inhibit growth by binding to different sites"><entity charOffset="0-10" id="DDI-PubMed.9155533.s2.e0" text="Paclitaxel" /><entity charOffset="12-16" id="DDI-PubMed.9155533.s2.e1" text="PTXL" /><entity charOffset="19-24" id="DDI-PubMed.9155533.s2.e2" text="Taxol" /><entity charOffset="29-35" id="DDI-PubMed.9155533.s2.e3" text="taxane" /><entity charOffset="41-52" id="DDI-PubMed.9155533.s2.e4" text="vinorelbine" /><entity charOffset="54-57" id="DDI-PubMed.9155533.s2.e5" text="VRB" /><entity charOffset="82-90" id="DDI-PubMed.9155533.s2.e6" text="alkaloid" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e0" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e4" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e0" e2="DDI-PubMed.9155533.s2.e6" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e1" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e4" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e1" e2="DDI-PubMed.9155533.s2.e6" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e2" e2="DDI-PubMed.9155533.s2.e2" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e2" e2="DDI-PubMed.9155533.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e2" e2="DDI-PubMed.9155533.s2.e4" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e2" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e2" e2="DDI-PubMed.9155533.s2.e6" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e3" e2="DDI-PubMed.9155533.s2.e3" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e3" e2="DDI-PubMed.9155533.s2.e4" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e3" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e3" e2="DDI-PubMed.9155533.s2.e6" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e4" e2="DDI-PubMed.9155533.s2.e4" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e4" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e4" e2="DDI-PubMed.9155533.s2.e6" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e5" e2="DDI-PubMed.9155533.s2.e5" /><pair ddi="false" e1="DDI-PubMed.9155533.s2.e5" e2="DDI-PubMed.9155533.s2.e6" /></sentence><sentence text=" We evaluated in vitro the antiproliferative activity of these two drugs as single agents and in combination, against two human melanoma cell lines, G361 and StM111a" /><sentence text=" The SRB (sulphorhodamine B) assay was used to determine growth inhibition"><entity charOffset="10-27" id="DDI-PubMed.9155533.s4.e0" text="sulphorhodamine B" /></sentence><sentence text=" Possible drug-drug interaction at the cellular level was assessed by constructing Isoboles (Isobologram analysis) and applying the concept of an 'envelope of additivity'" /><sentence text=" Both agents were active in the nanomolar range at clinically achievable concentrations" /><sentence text=" The mean IC50 for G361 was 46" /><sentence text="6 nM (PTXL) and 19"><entity charOffset="6-22" id="DDI-PubMed.9155533.s8.e0" text="PTXL" /></sentence><sentence text="9 nM (VRB) after a 1 h drug exposure"><entity charOffset="6-9" id="DDI-PubMed.9155533.s9.e0" text="VRB" /></sentence><sentence text=" Mean IC50 (1 h) for StM111a was 9" /><sentence text="7 nM (PTXL) and 26"><entity charOffset="6-8" id="DDI-PubMed.9155533.s11.e0" text="PTXL" /></sentence><sentence text="9 nM (VRB)"><entity charOffset="6-9" id="DDI-PubMed.9155533.s12.e0" text="VRB" /></sentence><sentence text=" Isobole analysis at the isoeffect levels of 25%, 50% and 75% indicated that drug interaction was predominantly synergistic (supra-additive) when paclitaxel and VRB were added concurrently for 1 h to cultures of StM11 1a or G361"><entity charOffset="146-156" id="DDI-PubMed.9155533.s13.e0" text="paclitaxel" /><entity charOffset="161-170" id="DDI-PubMed.9155533.s13.e1" text="VRB" /><pair ddi="false" e1="DDI-PubMed.9155533.s13.e0" e2="DDI-PubMed.9155533.s13.e0" /><pair ddi="false" e1="DDI-PubMed.9155533.s13.e0" e2="DDI-PubMed.9155533.s13.e1" /></sentence><sentence text=" In some experiments, this synergy was observed with particularly low concentrations of paclitaxel (3 nM) and VRB (0"><entity charOffset="88-98" id="DDI-PubMed.9155533.s14.e0" text="paclitaxel" /><entity charOffset="110-113" id="DDI-PubMed.9155533.s14.e1" text="VRB" /><pair ddi="false" e1="DDI-PubMed.9155533.s14.e0" e2="DDI-PubMed.9155533.s14.e0" /><pair ddi="false" e1="DDI-PubMed.9155533.s14.e0" e2="DDI-PubMed.9155533.s14.e1" /></sentence><sentence text="01 nM)" /><sentence text=" A new points were located within the envelope of additivity or in the subadditive (antagonism) region of the isobole" /><sentence text=" An overall synergy was also found if the data were analysed by the median effect analysis" /><sentence text=" The effect of these agents on the cytoskeleton and ultrastructure were studied with immunofluorescence and electron microscopy, respectively" /><sentence text=" These results confirm the in vitro inhibitory activity of paclitaxel and VRB against malignant melanoma, but more importantly the two drugs appear to act synergistically at relatively low concentrations"><entity charOffset="59-69" id="DDI-PubMed.9155533.s19.e0" text="paclitaxel" /><entity charOffset="74-83" id="DDI-PubMed.9155533.s19.e1" text="VRB" /><pair ddi="false" e1="DDI-PubMed.9155533.s19.e0" e2="DDI-PubMed.9155533.s19.e0" /><pair ddi="false" e1="DDI-PubMed.9155533.s19.e0" e2="DDI-PubMed.9155533.s19.e1" /></sentence><sentence text="" /></document>